Susan Yue
Senior Medical Director, Pharmacovigilance & Patient Safety Abbvie
Dr. Susan Yue has been in Clinical Development and Patient Safety for 16 years since moving from a nephrology clinical practice of 5 years. She has worked in large established biopharma companies as well as small biotherapeutic start ups. Currently she is a Group Medical Director in Early Development Oncology Patient Safety at AbbVie. Her focus centers on First In Human studies with antibody drug conjugates both in solid and hematologic oncology indications. She is committed to understanding, characterizing and communicating safety risks of ADCs, thereby allowing for effective safety management to ensure the protection of patients.
Seminars
Wednesday 5th November 2025
From Cell Painting to AI Assisted CT Scans: Holistically Using Science & Medicine to Better Monitor, Prevent & Detect Interstitial Lung Disease in Solid Tumor Patients Treated with ADCs
4:00 pm
- Evaluating distinctive trends in ADC clinical trials and real-world data to characterize areas for risk mitigation
- Establishing a non-clinical toolbox for comprehending pathophysiologic mechanism of action to support ADC asset design and screening
- Embracing innovative, non-traditional methods to elevate risk comprehension to better select patients or decrease incidence of ILD
